ReviewClinical reviews in allergy & immunology2025
Exploring Gut Microbiota in Systemic Lupus Erythematosus: Insights and Biomarker Discovery Potential.
Review in Clinical reviews in allergy & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Coordinated oral-gut microbiota relocation in connective tissue diseases: a systematic review.Frontiers in immunology · 2026Pooled it
- Review
- Probiotics in Autoimmune Disease: Strain-specific Mechanisms and Therapeutic Perspectives.Clinical reviews in allergy & immunology · 2026Review
- The integrative role of the microbiome in systemic immuno-inflammatory aberrations.Folia microbiologica · 2026Review
- Targeting the gut‒kidney axis for lupus nephritis treatment: multimechanism regulatory strategies and evidence from Traditional Chinese medicine.Chinese medicine · 2026Review
- Jieduquyuziyin prescription for systemic lupus erythematosus: a system-level therapeutic strategy for immunological recalibration.Chinese medicine · 2026Review
- Extracellular Vesicles of Streptococcus anginosus Mediate Gastritis via Epithelial Barrier Disruption and Macrophage-driven Inflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Polydopamine-Encapsulated Probiotics Restore Gut Homeostasis and Reinstate Macrophage Efferocytosis in Systemic Lupus Erythematosus.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Metabolic Calibration of Female Immune Plasticity: From X-Linked Vulnerability to Precision Metabotyping.Biology · 2026Review
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- The type 1 and type 3 immune responses underlying the tissue inflammation associated with NOX2 deficiency.Frontiers in immunology · 2026Review
- The Gut Microbiota: Emerging Evidence in Autoimmune and Inflammatory Diseases.Research (Washington, D.C.) · 2026Review
- Composition of and changes in faecal microbiota in children diagnosed with oligoarticular juvenile idiopathic arthritis.Frontiers in medicine · 2026Article
- Efficacy of adjuvant chemotherapy in patients with late-onset stage II/III colon cancer: a retrospective cohort study.Open medicine (Warsaw, Poland) · 2026Article
- Traditional Chinese medicine and plant metabolites for rheumatoid arthritis via modulating gut microbiota: a scoping review evaluating the transition from correlation to causality.Frontiers in pharmacology · 2026Review
- The landscape of cellular immune alteration in systemic lupus erythematosus.Frontiers in immunology · 2026Review
- Activation of aryl hydrocarbon receptor signaling by indole-3-lactic acid from Bacillus velezensis DS2 reinforces gut mucosal immunity and attenuates inflammaging in aged mice.Immunity & ageing : I & A · 2025Article
- Association of Gut Dysbiosis with Disease Phenotype and Treatment in Systemic Lupus Erythematosus.Medical sciences (Basel, Switzerland) · 2025Article
- Extracellular Vesicles Derived From Streptococcus anginosus Aggravate Lupus Nephritis by Triggering TLR2-MyD88-NF-κB Signalling in NK Cells.Journal of extracellular vesicles · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease characterized by chronic inflammation and multi-organ damage, influenced by genetic, environmental, and immunological factors. Recent research highlights the significant role of gut microbiota in the pathogenesis and progression of SLE, suggesting that dysbiosis-an imbalance in the microbial community-can contribute to disease onset and severity. The gut microbiota, through its metabolites, interacts with the host's immune system, influencing immune responses and maintaining intestinal barrier integrity. These interactions have positioned the gut microbiota as a potential source of diagnostic biomarkers and therapeutic targets for SLE. This review delves into the mechanisms by which gut microbiota influences SLE, exploring how alterations in microbial composition and function can trigger autoimmune responses. We also examine the potential of gut microbiota-derived metabolites as biomarkers for early diagnosis and disease progression monitoring. Additionally, the therapeutic implications of modulating gut microbiota through dietary interventions, probiotics, prebiotics, and other microbiota-targeted therapies are discussed as promising strategies for managing SLE. The findings suggest that a deeper understanding of the gut microbiota's role in SLE could lead to more personalized and effective treatments, potentially transforming the approach to managing this chronic autoimmune condition. Future research should focus on elucidating the precise mechanisms of gut microbiota interaction with the immune system and its impact on SLE, as well as validating gut microbiota-based biomarkers and therapies in clinical settings.
Indexed as
Identifiers
40216660What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.